TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06863272: MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 360 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,295,910

Rescue Site Savings

+$863,940

Unlock Full NCT06863272 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06863272 Rescue Dossier →